Feasibility of transdermal transport of atenolol  by combination of iontophoresis and oleic acid  pretreatment

Akhmad Kharis Nugroho; Arief Rahman Hakim; Marlyn Dian Laksitorini; Fajar Rakhmatullah; Eny Masruriati

doi:10.14499/indonesianjpharm0iss0pp65-72

Feasibility of transdermal transport of atenolol by combination of iontophoresis and oleic acid pretreatment

Akhmad Kharis Nugroho, Arief Rahman Hakim, Marlyn Dian Laksitorini, Fajar Rakhmatullah, Eny Masruriati

Abstract

Atenolol has a low oral bioavailability and a short elimination half-life. Therefore, alternative route and delivery system is important. Transdermal iontophoresis, i.e. a systemic drug delivery via the skin, implementing a low intensity of electrical current, is one attractive candidate. This study evalu ated feasibility of atenolol transdermal transport when iontophoresis is applied after enhancer pretreatment. There were 4 formulas prepared; 2 implemented iontophoresis for 3 hours (current density: 0.25 mA/cm²) while the others did not use iontophoresis. The enhancer was oleic acid (5 or 10% as a mixture in propylene glycol) with duration of pretreatment of one hour. Transport was evaluated in the diffusion studies across the fresh rat skin in a static-vertical diffusion system. Data were analyzed based on the numeric convolution method to obtain simulated Cp profiles as well as AUC of Cp profiles. Based on the simulated Cp, the best transport was achieved in Formula 3, where iontophoresis is performed across the skin, pretreated with 5% oleic acid for one hour. The value of simulated Cp indicated achievement of therapeutics level of atenolol, suggesting the feasibility of the atenolol delivery by iontophoresis.

Key words : atenolol, transdermal, iontophoresis, enhancer

Full Text:

Untitled

References

Anonymous 2009, Tenormin (Atenolol Tablets) Drug Information: Uses, Side Effects, Drug Interactions and Warnings at RxList. Available at: http://www.rxlist.com/atenololdrug.htm [Accessed January 6, 2010].

Anroop, B., Ghosh, B., Parcha, V. and Khanam, J. 2009, Transdermal delivery of atenolol: effect of prodrugs and iontophoresis. Curr Drug Deliv, 6 (3), pp.280-290.

Inal, O., Kiliçarslan, M., Ari, N. and Baykara, T. 2008, In vitro and in vivo transdermal studies of atenolol using iontophoresis. Acta Pol Pharm, 65(1), 29-36.

Jiang, S.J., Hwang, S.M., Choi, E.H., Elias, P.M., Ahn, S.K. & Lee, S.H. 2000, Structural and functional effects of oleic acid and iontophoresis on hairless mouse stratum corneum. J. Invest. Dermatol, 114(1),64-70.

Larrucea, E., Arellano, A., Santoyo, S. and Ygartua, P. 2001, Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. Eur J Pharm Biopharm, 52(2),113-119.

Luzardo-Alvarez, A., Rodríguez-Fernández, M., Blanco-Méndez, J., Guy, R.H. and Delgado-Charro, M.B. 1998, Iontophoretic permselectivity of mammalian skin: characterization of hairless mouse and porcine membrane models. Pharm. Res, 15(7), 984-987.

Mason, W.D., Winer, N., Kochak, G., Cohen, I. and Bell, R. 1979, Kinetics and absolute bioavailability of atenolol. Clin. Pharmacol. Ther, 25(4), 408-415.

Murakami, T., Yoshioka, M., Yumoto, R., Higashi, Y., Shigeki, S., Ikuta, Y. and Yata, N. 1998, Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats. J. Pharm. Pharmacol, 50(1), 49-54.

Nair, A., Reddy, C. and Jacob, S. 2009, Delivery of a classical antihypertensive agent through the skin by chemical enhancers and iontophoresis. Skin Res Technol, 15(2),187-194.

Nugroho, A.K. 2005, Transdermal Iontophoretic Delivery of Dopamine Agonists: In Vitro - In Vivo Correlation Based on Novel Compartmental Modeling.

Nugroho, A.K., Li, G., Grossklaus, A., Danhof, M. and Bouwstra, J.A. 2004, Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro. J Control Release, 96(1), 159-67.

Nugroho, A.K., Li, L., Dijkstra, D., Wikström, H., Danhof, M. and Bouwstra, J.A. 2005, Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. J Control Release, 103(2), 393-403.

Puglia, C. and Bonina, F. 2008, Effect of polyunsaturated fatty acids and some conventional penetration enhancers on transdermal delivery of atenolol. Drug Deliv, 15(2),107-112.

Qi, X., Liu, R.R., Sun, D., Ackermann, C. and Hou, H. 2003, Convolution method to predict drug concentration profiles of 2,3,5,6-tetramethylpyrazine following transdermal application. Int. J . Pharm, 259(1-2), 39-45.

Vogelpoel, H., Welink, J., Amidon, G.L., Junginger, H.E., Midha, K.K., Möller, H., Olling, M., Shah, V.P. and Barends, D.M. 2004, Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J . Pharm Sci, 93 (8), 1945-1956.

Wan, S.H., Koda, R.T. and Maronde, R.F. 1979, Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol, 7 (6), pp.569-574.

Welin-Berger, K., Neelissen, J.A.M., Emanuelsson, B., Björnsson, M.A. and Gjellan, K. 2003, In vitro-in vivo correlation in man of a topically applied local anesthetic agent using numerical convolution and deconvolution. J Pharm Sci, 92 (2), pp.398-406.

Yu, B., Kim, K.H., So, P.T.C., Blankschtein, D. and Langer, R. 2003, Visualization of oleic acidinduced transdermal diffusion pathways using two-photon fluorescence microscopy. J. Invest. Dermatol, 120(3),448-455.

Anroop, B., Ghosh, B., Parcha, V. and Khanam, J. 2009, Transdermal delivery of atenolol: effect of prodrugs and iontophoresis. Curr Drug Deliv, 6 (3), 280-290.

Inal, O., Kiliçarslan, M., Ari, N. and Baykara, T. 2008, In vitro and in vivo transdermal studies of atenolol using iontophoresis. Acta Pol Pharm, 65 (1), 29-36.

Jiang, S.J., Hwang, S.M., Choi, E.H., Elias, P.M., Ahn, S.K. and Lee, S.H. 2000, Structural and functional effects of oleic acid and iontophoresis on hairless mouse stratum corn eum. J. Invest. Dermatol, 114 (1), 64-70.

Mason, W.D., Winer, N., Kochak, G., Cohen, I. and Bell, R. 1979, Kinetics and absolute bioavailability of atenolol. Clin. Pharmacol. Ther, 25(4),408-415.

Nair, A., Reddy, C. and Jacob, S. 2009, Delivery of a classical antihypertensive agent through the skin by chemical enhancers and iontophoresis. Skin Res Technol, 15 (2), 187-194.

Nugroho, A.K. 2005, Transdermal Iontophoretic Delivery of Dopamine Agonists: In Vitro - In Vivo Correlation Based on Novel Compartmental Modeling.

Puglia, C. and Bonina, F. 2008, Effect of polyunsaturated fatty acids and some conventional penetration enhancers on transdermal delivery of atenolol. Drug Deliv, 15 (2), pp.107-112.

Qi, X., Liu, R.R., Sun, D., Ackermann, C. & Hou, H. 2003, Convolution method to predict drug concentration profiles of 2,3,5,6-tetramethylpyrazine following transdermal application. Int J Pharm, 259 (1-2), pp.39-45.

Wan, S.H., Koda, R.T. and Maronde, R.F. 1979, Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol, 7 (6),569-574.

DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp65-72